The economic burden of tuberculosis in the European Union far outweighs the cost of investing in more efficient vaccines against TB.

Today and the coming days Euronews television will broadcast a documentary about the development of one of the promising tuberculosis vaccine candidates in TBVI's portfolio. The documentary was developed with financial support of the European Commission, and highlights one of the results of the NEWTBVAC project and its predecessor TBVAC. Both projects were/are coordinated by TBVI.

The vaccine candidates MTBVAC, developed by the University of Zaragoza and produced by BIOFABRI, and HBHA, developed by Institute Pasteur Lille and produced in collaboration with AERAS, have been awarded with financial support for further development.  BIOFABRI will receive $ 430,000 to support a PhaseI clinical trial carried out by Centre Hospitalier Universitaire Vaudois, Lausanne. Institut Pasteur Lille, will receive $ 350,000 for HBHA to fund GMP production of HBHA and studies to select an adjuvant.

Read the newsletter here.

Brussels/Lausanne/Zaragoza/Lelystad, 16 October 2012 – European scientists are one step closer to delivering a new, safe and more effective vaccine against tuberculosis. Swiss-medic, the Swiss regulatory authority for medicine has given permission to start assessing the new TB vaccine in healthy adult volunteers. The vaccine, called MTBVAC, is the first vaccine of its kind to start clinical evaluation.

TBVI has opened the following Call for proposals:
Deadline:  17:00 CEST, 11 September 2012

Researchers are well on their way to deliver a solution against the growing threat of tuberculosis. New vaccines will have significant impact on the number of cases, eventually eliminating the disease. In order to deliver these live-saving vaccines, intense collaboration and commitment are crucial. In 2011, TuBerculosis Vaccine Initiative (TBVI) has stepped up collaboration on all levels, through new projects, partnerships and strategies. Today the organisation launches its 2011 Annual Report.

TuBerculosis Vaccine Initiative (TBVI), a non-profit organisation that supports the development of urgently needed new vaccines against tuberculosis (TB), will receive a new grant from the Bill & Melinda Gates Foundation. With the award of up to 3 million dollars spread over 3 years, TBVI can support the development of several TB vaccine candidates and contribute to the fight against this ghastly disease.

The Stop TB Partnership Working Group on New TB Vaccines presents the Tuberculosis Vaccine Candidates 2011, as an update of the 2009 Pipeline.

Spain/The Netherlands, 29 February 2012 – Biopharmaceutical company Biofabri (Porrino, Spain) has decided to financially support the TuBerculosis Vaccine Initiative (TBVI), a European foundation based in the Netherlands. The two organisations have signed a sponsorship agreement with the aim to strengthen TBVI’s activities in the search for new vaccines that are able to protect future generations against tuberculosis. Besides financial support, Biofabri will provide TBVI with strategic advice by taking a seat in the Council of Trustees.